INTRAVESICAL CHEMOTHERAPY FOR NON-MUSCLE INVASIVE BLADDER CANCER (40-44)

Список литературы: 1.European Association of Urology Guidelines 2019 2.Ferlay J, et al. GLOBOCAN 2012 vl.0: Estimated cancer •inciden’eermortality and prevalence worldwide in 2012, 2013. 20*5. 3.Burger, М., et al. Epidemiology and risk factors of urothelial bladder cancer. Eur Urph 2013. 63: 234, 4. Cancer in Ukraine, Bulletin of the National Cancer Registry of Ukraine 2019. 5.Gantsev Sh.Kh., Zimichev A.A., Pryanichnikova M.B., Maklakov V.N. Features of the complex multifactorial risk assessment of bladder cancer // Kuban Research Medical Gazette. – 2010. – №3-4. – P. 47-49. 6.Zavyalova E.S., Al’-Shukri A.S., Korneev I.A., Yagmur O.D. Role of antigens Ki-67, p53 and bcl-2 in predicting the clinical course of transitional cell bladder cancer // Nephrol-ogy. –2009. – Vol. 13, №1. – P. 9094. 7.Zavyalova E.S., Korneev I.A., Yagmurov O.D., Al’-Shukri A.S. The value of the classical morphological traits for predicting the course of transitional cell bladder cancer // Nephrol-ogy. – 2010. – Vol. 14, №1. – P. 81-85. 8.Zimichev A.A. Pryanichnikova M.B., Fedorina T.A., Shuvalova T.V., Maklakov V.N. Nizamova R.S., Bogdanov S.N. Morphological and mathematical evaluation of the role of factors predicting the longterm results of treatment of bladder cancer // Creative Surgery and Oncology. – 2010. – №4. – P. 33-35. 9.Andreyeva YuU, Frank GA. Tumors of the urinary system and male genital organs. Morphological diagnostics and genetics: A manual for doctors. M.: Practical medicine; 2012. 216 p. 10.Epstein JI, Amin MB, Reuter VR et al. The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Am J Surg Pathol 1998 Dec;22(12): 1435^18. 11.El-Bolkainy MN, Mokhtar NM, Ghoneim MA and Hussein MH: The impact of schistosomiasis on the pathology of bladder carcinoma. Cancer 1981; 48: 2643, Mostafa MH, Sheweita SA and O'Connor PJ: Relationship between schistosomiasis and bladder cancer. Clin Microbiol 1999; 1:972. 12.Burger M, van der Aa MN, van Oers JM et al. Prediction of Progression of Non Muscle-Invasive Bladder Cancer by WHO 1973 and 2004 Grading and by FGFR3 Mutation Status: A Prospective Study. Eur Urol 2008 Oct;54(4):835-44. 13.Pan CC, Chang YH, Chen KK et al. Prognostic significance of the 2004 WHO/ISUP classification for prediction of recurrence, progression, and cancerspecific mortality of non-muscle-invasive urothelial tumors of the urinary bladder: a clinicopathologic study of 1,515 cases. Am J Clin Pathol 2010 May;133(5):788-95. 14.Ponukalin A.N., Glybochko P.V., Blumberg B.I., Galkina N.G., Mikhailov V. Yu. Effect of method of urine derivation in the long-term outcomes and quality of life in patients with bladder cancer after radical cystectomy // Medical Bulletin of Bashkortostan. – 2011. – Vol. 6, №2. – P. 195-200. 15.Ponukalin A.N., Maslyakova G.N., Tsmokalyuk E.N. Evaluation of the effectiveness of different immunohistochemi-cal markers in the staging and prognosis of muscle-invasive bladder cancer // Saratov Journal of Medical Science. – 2014. – Vol. 10, №1. – P. 124-128. 16.Sivkov A.V., Roshchin D.A., Perepechin D.V., Nikonova L.M., Polozhentseva M.O. Molecular genetic markers of bladder cancer in clinical practice // Experimental and Clinical Urology. – 2013. – №3. – P. 48-55. 17.Sinitsyna O.V., Chonkina A.A., Ilyushkina M.V., Dolgikh D.V. Molecular genetic risk assessment method unfavorable course of the disease in superficial bladder cancer // Medical alphabet. – 2014. – Vol. 3, №15. – P. 56-57. 18.Traksov I.S., Plotnikova N.A., Kemaykin S.P., Khari-tonova T.V. Features of incidence of bladder cancer in different population groups of the Republic of Mordovia (data for 2010) // Magazine of Scientific Articles and Health Education in the XXI century. – 2013. – Vol. 15, № 1-4. – P. 358-359. 19.Gao W., Romkes M., Zhong S., Nukui T., Branch R., Keo-havong P., Persad R. A., Smith P. J. B. Genetic polymorphisms in the DNA repair genes XPD and XRCC1, p53 gene mutations and bladder cancer risk // Oncology Reports. – 2010. – Vol. 24, №1. – P. 257-262. 20.Zabolotneva A.A., Gaifullin N.M., Buzdin A.A., Alekseev B.Ya., Andreeva Yu. Yu., Shegay P.V., Sokov D.G., Rusakov I.G. Molecular markers for bladder cancer: from the private to the whole // Oncourology. – 2011. – №3. – P. 16-19. 21.Derzhavets L.A. Laboratory findings and survival of patients suffering from bladder cancer // Siberian Journal of Oncology. – 2013. – №4 (58). – P. 12-16. 22.Zavyalova E.S., Al’-Shukri A.S., Korneev I.A., Yagmur O.D. Role of antigens Ki-67, p53 and bcl-2 in predicting the clinical course of transitional cell bladder cancer // Nephrol-ogy. –2009. – Vol. 13, №1. – P. 9094. 23. Nargund V. H., Tanabalan C. K., Kabir M. N. Management of non-muscle-invasive (superficial) bladder cancer // Seminars in Oncology. – 2012. – Vol. 39, №5. – P. 59-72. 24.Caprina A.D., Starinskiy V.V., Petrova G.V. State of oncology care to the population of Russia in 2012. – M .: FGBI «MNIOI named after P.A. Herzen» Health Ministry of Russia. – 2013. – 232 p. 25.Lelyavin V.K., Dvornichenko V.V. Musclenoninvasive bladder cancer: clinical and morphological features, treatment outcomes, survival analysis // Bulletin of the East Siberian Scientific Center of the Academy of Medical Sciences. – 2013. – №5 (93). – P. 53-59. 26.Gadaborshev M.I., Levkevich M.M. Problems of organization providing urologic care to the population (for example, the Krasnodar Territory) // Siberian School of Finance. – 2012. – № 2. – P. 22-28. 27.Babayan A.Yu., Karyakin O.B., Teplov A.A., Zaletaev D.V., Nemtsova M.V. Molecular genetic changes that determine the pathogenesis of superficial and invasive bladder cancer // Molecular Biology. – 2011. – Vol. 45, №6. – P. 1012-1016. 28.Zimichev A.A., Pryanichnikova M.B., Maklakov V.N. An integrated approach to forecasting long-term results of treatment of bladder cancer // Urology. – 2010. – №3. – P. 47-49. 29.Pavlov V.N., Izmailov A.A., Izmailova S.M., Kazikhinurov A.A., Urmantsev M.F. Genetic markers of prognosis of recurrence of superficial bladder cancer // Urals Medical Journal. – 2012. – №3. – P. 20-23. 30. Schenk-Braat E.A., Bangma C.H. Immunotherapy for superficial bladder cancer. Cancer Immunol Immunother. 2005; 54(5):414−23. 31.Jalón Monzón A., Fernández Gómez J.M., Escaf Bramada S. et al.Therapeutic effect of immediate postoperative mitomycin C in patients with low-risk non-muscle-invasive bladder tumors. Actas Urol Esp 2008;32(8):811−20. 32.Jahnson S., Wiklund F., Duchek M., Mestad O., Rintala E., Hellsten S., Malmström P.U. Results of secondlook resection aſter primary resection of T1 tumour of the urinary bladder // Scand. J. Urol. Nephrol. 2005. Vol. 39(3). P. 206–210. 33.Divrik R.T., Yildirim U., Zorlu F., Ozen H. Te effect of repeat transurethral resection on recurrence and progression rates in patients with T1 tumors of the bladder who received intravesical mitomycin: a prospective, randomized clinical trial // J. Urol. 2006. Vol. 175(5). P. 1641–1644. 34.Sylvester R.J., Oosterlinck W., Witjes J.A. Te schedule and duration of intravesical chemotherapy in patients with non muscle invasive bladder cancer: a systematic review of the published results of randomized clinical trials // Eur. Urol. 2008. Vol. 53(4). P. 709–719. 35.Huncharek M., McGarry R., Kupelnick B. Impact of intravesical chemotherapy on recurrence rate of recurrent superficial transitional cell carcinoma of the bladder: results of a meta-analysis // Anticancer. Res. 2001. Vol. 21(1B). P. 765–769. 36.Witjes J.A. et al. Comprehensive Textbook of Cenitourinarv Oncology / Vogelzang N.J., Scardino P.T., Shipley W.T.J., Coffcy D.S. eds.). – Philadelphia, PA: Williams and Wilkins, 1996. – P. 416427. 37.Zein Т.А. et al. Bone marrow suppression after intravesical mitomycin С treatment // J. Urol. – 1986. – Vol.136. – P. 459460.56. Zhang S. et al. The preventive recurrent results of postoperative intra-vesical instillation therapy in bladder cancer // Chung Hua Wai Ко Tsa Chih. – 1995. – Vol.33(5). – P. 304306. 38Eijstein A. et al. Reduced bladder capacity in patients receiv-ing intravesical chemoprophylaxix with milumycin C // Brit. J. Urol. – 1990. – Vol.66. – P. 386. 39.Kamat A.M., DeHaven Л., Lamm D.L. // Urology. – 1999. – V. 54 (1). – P. 56–61. 40.Rajala P., Liukkonen T., Raitanen M. et al. // J. Urol. – 1999. – V. 161 (4). – P. 1133–1135. 41.Mungan N.A., Witjes J.A. // Brit. J. Urol. – 1998. – V. 82 (2). – P. 213–223. 42.Zincke H., Utz D.C., Taylor W.F. et al. // J. Urol. – 1983. – V. 129 (3). – P. 505–509. 43.Soloway M.S. et al. Thiotepa induced myelosupression: a review of 670 blad-der instillations // J. Urol. – 1983. – Vol.130.– P. 889891. 44.Connolly J.G. Chemotherapy of superficial bladder cancer // Carcinoma of the bladder / Connolly J.G., ed. – Raven, New York, 1981. – P. 165-175.